Investors have a tendency to fixate on the negative instead of seeing the bigger bullish picture. Because of this, they often overreact to the slightest bad news and rush for the exits. For the more level-headed traders out there, this can lead to great opportunities. #-ad_banner-# Gilead Sciences (Nasdaq: GILD) is a prime example of this. Due in part to investor overreactions, this biopharmaceutical company may be one of the most undervalued stocks in its sector. Gilead offers consistent earnings growth, and analysts… Read More
Investors have a tendency to fixate on the negative instead of seeing the bigger bullish picture. Because of this, they often overreact to the slightest bad news and rush for the exits. For the more level-headed traders out there, this can lead to great opportunities. #-ad_banner-# Gilead Sciences (Nasdaq: GILD) is a prime example of this. Due in part to investor overreactions, this biopharmaceutical company may be one of the most undervalued stocks in its sector. Gilead offers consistent earnings growth, and analysts expect it to earn $12.08 per share this year and $12.42 per share next year. With shares trading at $82.70, GILD has a forward price-to-earnings (P/E) ratio of less than 7, which is a bargain considering that the average forward valuation in the biotech industry is 25. Other large drug companies with stable earnings — like Merck (NYSE: MRK) and Pfizer (NYSE: PFE) — often trade with forward multiples above the industry average. If GILD were valued at just half the industry average (which I believe is a fair assumption), shares would trade around $150 — more than 80% above… Read More